BCG Vaccine
-
Subject Areas on Research
- A critical role for CD8 T cells in a nonhuman primate model of tuberculosis.
- A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results.
- Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal.
- Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine.
- Adoptive transfer and specific active immunization of patients with malignant melanoma.
- Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
- Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage.
- Comparison of altitude effect on Mycobacterium tuberculosis infection between rural and urban communities in Peru.
- Current issues in global tuberculosis control.
- Cutaneous complications of BCG vaccination in infants with immune disorders: two cases and a review of the literature.
- Detection of bloodstream pathogens in a bacille Calmette-Guérin (BCG)-vaccinated pediatric population in Malawi: a pilot study.
- Differentiation of strains in Mycobacterium tuberculosis complex by DNA sequence polymorphisms, including rapid identification of M. bovis BCG.
- Disseminated bacille Calmette-Guérin disease after vaccination.
- Disseminated bacille Calmette-Guérin disease after vaccination: case report and review.
- Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection.
- Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates.
- Enhancement of macrophage-mediated tumor cell killing by bacterial outer membrane proteins (porins).
- Epidemiology of bloodstream infections in a bacille Calmette-Guérin-vaccinated pediatric population in Malawi.
- Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System.
- Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
- Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.
- From Dog's Breakfast to Michelin Guide: Post-bacillus Calmette-Guérin Trials in Non-muscle-invasive Bladder Cancer.
- HLA-B7 associated tuberculin hyporesponsiveness in BCG treated melanoma patients.
- Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells. Production of reactive antisera and absence of EAE induction.
- Hyperthermia and intravesical therapy: emerging one-two punch for bladder cancer?
- Immunobiology of human gliomas.
- Immunobiology of primary intracranial tumors.
- Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer.
- Immunotherapy for malignant melanoma with a tumor cell vaccine.
- Impact of Bacillus Calmette-Guérin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection.
- Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells.
- Interferon-gamma release assays piloted as a latent tuberculous infection screening tool in Canadian federal inmates.
- Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
- Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
- Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
- Intravesical therapy use in the high risk patient: practice patterns in an equal access healthcare institution before and after national guidelines.
- Investigational therapies for non-muscle invasive bladder cancer.
- Macrophage tumor killing: influence of the local environment.
- Maintenance bacillus Calmette-Guérin: why is there continued debate?
- Management of recurrent melanoma of the extremity.
- Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19.
- Mycobacterium tuberculosis Evasion of Guanylate Binding Protein-Mediated Host Defense in Mice Requires the ESX1 Secretion System.
- NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
- Non-specific and specific active immunotherapy in a B16 murine melanoma system.
- Prevention of glioma induction in rats by simultaneous intracerebral inoculation of avian sarcoma virus plus bacillus Calmette-Guerin cell-wall preparation.
- Re: Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
- Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.
- Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.
- Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites.
- Relational Mobility Predicts Faster Spread of COVID-19: A 39-Country Study.
- Reply by Authors.
- Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
- Skin complications of Bacillus Calmette-Guérin immunization.
- Specific active immunotherapy for melanoma.
- Specific cytotoxic antibody in the sera of patients with melanoma.
- Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer.
- Successful treatment of disseminated BCG in a patient with severe combined immunodeficiency.
- The challenges of an HIV vaccine enterprise.
- The impact of the social construct of race on outcomes among bacille Calmette-Guérin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting.
- The role of transmethylation reactions in regulating the binding of BCG-activated murine macrophages to neoplastic target cells.
- Treatment of superficial carcinoma of the bladder.
- Tuberculin reactivity in bacille Calmette-Guérin vaccinated populations: a compilation of international data.
- Tuberculosis Susceptibility and Vaccine Protection Are Independently Controlled by Host Genotype.
- [Basis for a specific-active immunotherapy in malignant melanoma].
-
Keywords of People
- Inman, Brant Allen, Professor of Surgery, Surgery, Urology